Log In Sign up
The largest database of trusted experimental protocols

Anti ccr7 alexa fluor 647

Manufactured by BD
Visit Supplier

Anti-CCR7 Alexa Fluor 647 is a fluorescently labeled antibody that specifically binds to the CCR7 chemokine receptor. Alexa Fluor 647 is the fluorescent dye conjugated to the antibody, providing a way to detect and analyze CCR7-expressing cells.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd56 alexafluor700, by BioLegend (1 mentions) Anti cd3 bv711, by BioLegend (1 mentions) Anti cd4 pe cy5, by BioLegend (1 mentions) Anti cd8 bv605, by BioLegend (1 mentions) Anti cd19 percp cy5, by BioLegend (1 mentions) Anti cd14 pe, by BD (1 mentions) Anti cd16 bv785, by BioLegend (1 mentions) Anti cd45ra pe cy7, by BioLegend (1 mentions) Lsrfortessa, by BD (1 mentions) Anti pd 1 pe, by BioLegend (1 mentions) Anti hla a2 fitc, by BD (1 mentions) Fab32652p, by R&D Systems (1 mentions) Goat anti human igg f ab 2 biotin, by Bio-Rad (1 mentions) Streptavidin apc, by Bio-Rad (1 mentions) Anti cd86 percp cy5, by BD (1 mentions) Anti tim3 apc, by BioLegend (1 mentions) Facs cantoi 2, by BD (1 mentions) Anti cd8 bv421, by BD (1 mentions)

Close spelling variants of this product

CCR7-Alexa 647 Alexa Fluor 647 Alexa 647 Anti-CCR7

2 protocols using anti ccr7 alexa fluor 647

1

Multiparametric Flow Cytometry Analysis of Immune Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
The subsets of T lymphocytes14 (link),15 (link) and monocytes12 (link),13 (link) at baseline and at following timepoints during PU-H71 treatment were monitored by flow cytometry. Peripheral blood (PB) cells from healthy donor was used as a control. Cells were isolated by the Ficoll-Paque method from PB and bone marrow (BM) aspirates. Cells were labeled with anti-CD45 APC-H7, anti-CD33 BV650 (BD Biosciences, clone WM53, cat. 303430), anti-CD56 AlexaFluor700 (BioLegend, clone HCD56, cat. 318316), anti-CD3 BV711 (BioLegend, clone SK7, cat. 344838), anti-CD4 PE-Cy5 (BioLegend, clone OKT4, cat. 317412), anti-CD8 BV605 (BioLegend, clone SK1, cat. 344742), anti-CD19 PerCP/Cy5.5 (BioLegend, clone HIB19, cat. 302230), anti-CD14 PE (BD Biosciences, clone M5E2, cat. 555398), anti-CD16 BV785 (BioLegend, clone 3G8, cat. 302046), anti-CD45RA PE-Cy7 (BioLegend, clone HI100, cat. 304126) and anti-CCR7 Alexa Fluor 647 (BD Biosciences, clone 150503, cat. 560816). After washing, flow cytometry evaluation was performed on BD LSRFortessa. Data was analyzed using FlowJo software.
Sugita M., Wilkes D.C., Bareja R., Eng K.W., Nataraj S., Jimenez-Flores R.A., Yan L., De Leon J.P., Croyle J.A., Kaner J., Merugu S., Sharma S., MacDonald T.Y., Noorzad Z., Panchal P., Pancirer D., Cheng S., Xiang J.Z., Olson L., Van Besien K., Rickman D.S., Mathew S., Tam W., Rubin M.A., Beltran H., Sboner A., Hassane D.C., Chiosis G., Elemento O., Roboz G.J., Mosquera J.M, & Guzman M.L. (2021). Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precision Oncology, 5, 44.
+ Open protocol
+ Expand
2

Mesothelin Expression on Human T-cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
CAR Mesothelin surface expression on human T-cells was assessed using primary antibody goat anti-human IgG F (ab’)2 Biotin (BioRad, Hercules, CA) along with secondary conjugate Streptavidin APC (BioRad). The following antibodies were also used in FACS buffer in this study: anti-PD1-PE (Biolegends 329906), anti-CCR7-Alexa-fluor 647 (BD 560921), anti-CD8-FITC (BC A07756), anti-CD8-BV421 (BD 562428), anti-HLA-A2-FITC (BD 551,285), anti-CD86-PerCp-Cy5.5 (BD 561129), anti-CLDN6-Dylight 650 (IMAB027), anti-idiotype-IMAB027- Alexa-fluor 647, anti-TIM3-APC (Biolegends 345011) and 7AAD (BC A07704). Mesothelin expression was detected using the PE conjugated anti mesothelin antibody (R&D system FAB32652P). Acquisition and analysis of all samples were performed on a BD FACS CantoI/II (BD Biosciences, San Jose, California) and FlowJo software (v7.6.1).
Alishah K., Birtel M., Masoumi E., Jafarzadeh L., Mirzaee H.R., Hadjati J., Voss R.H., Diken M, & Asad S. (2021). CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. Journal of Translational Medicine, 19, 482.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!